Michael P. Eaton, MD

Dr. Michael Eaton’s general area of interest is the interaction of cardiopulmonary bypass with human blood, and the minimization of the adverse effects of this interaction. This is of particular importance in pediatric and neonatal cardiac surgery, where available knowledge is significantly less and patients are at higher risk due to an immature hemostatic system and the greater degree of hemodilution involved. Currently Dr. Eaton is investigating exploring a novel combination anticoagulant strategy for cardiopulmonary bypass without heparin using closed loop cardiopulmonary bypass models. He has a clinical trial underway randomizing infants undergoing cardiac surgery with cardiopulmonary bypass to supplementation with antithrombin III or placebo. He is also completing a study investigating the ability of traditional tube-based ACT testing compared with cartridge-based ACT devices to measure thrombin generation during bypass